Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

2012 Archives

12/10/2012

Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND

Evidence of Long-Term Cell Survival

11/09/2012

Neuralstem Reports Third Quarter Financial Results And Provides Update On Clinical Programs And Business Highlights

10/17/2012

FDA Approves Neuralstem To Treat Second Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder

First Ib Patient Treated in Escalated Dosing of Neurogenic Small Molecule Drug

10/15/2012

Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke Rats With Neuralstem NSI-566 Cells

10/10/2012

Neuralstem To Present Preclinical Data At Neuroscience 2012, 42nd Annual Meeting Of The Society For Neuroscience

Five Presentations Span Two Platforms: Stem Cell Therapy and Neurogenic Compounds

10/09/2012

Dr. Eva Feldman, Principal Investigator, Updates Interim Data On Completed Neuralstem ALS Phase I Trial

10/04/2012

Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial

09/27/2012

Neuralstem Approved To Commence Ischemic Stroke Trial In China

09/24/2012

Neuralstem President And CEO To Present At The 2012 Aegis Healthcare Conference

09/19/2012

Neuralstem Announces Closing of $7 Million Registered Direct Offering

09/13/2012

Neuralstem to Raise $7.0 Million in Registered Direct Offering

09/13/2012

Neuralstem Announces Proposed Public Offering

09/13/2012

Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports

Paralyzed Rats Regain Use of Lower Limbs

09/11/2012

Neuralstem CSO, Dr. Karl Johe, To Speak At 6th Neurodegenerative Conditions Research and Development Conference

09/10/2012

Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference

Live Webcast on Tuesday, September 11 at 2:00 p.m. EDT

09/06/2012

Neuralstem Grants First Licenses For CNS Therapy Surgical Devices

Industry-breakthrough Spinal Platform and Floating Cannula Used in ALS Stem Cell Trial

08/27/2012

Neuralstem Completes Phase I ALS Stem Cell Trial

08/15/2012

Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.

08/14/2012

Neuralstem Announces Pricing Of Public Offering Of 6,000,000 Shares Of Common Stock

08/10/2012

Neuralstem Reports Second Quarter Financial Results And Provides Clinical Program And Business Highlights

07/26/2012

Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions

07/25/2012

Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial

06/25/2012

First Patients Dosed in Ib Phase of Neuralstem's NSI-189 Trial in Major Depressive Disorder

06/19/2012

Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial

First To Receive Treatment In Upper And Lower Spinal Cord

06/05/2012

Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

1-25 26-35

Press Releases

2012 Archives

Information for Investors